Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Multiple Myeloma 81Neoplasms, Plasma Cell 27Neoplasms 13Brain Neoplasms 11Prostatic Neoplasms 10Central Nervous System Neoplasms 10Melanoma 9Leukemia 9Glioblastoma 8Gliosarcoma 7Glioma 7Leukemia, Lymphocytic, Chronic, B-Cell 6Carcinoma, Hepatocellular 6Recurrence 5Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Lung Neoplasms 5Waldenstrom Macroglobulinemia 4Sarcoma 4Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Immunoglobulin Light-chain Amyloidosis 4Carcinoma, Renal Cell 4Uveal Melanoma 3Oligodendroglioma 3Neuroblastoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3

Interventions

Ipilimumab 16incomplete Freund's adjuvant 9Nivolumab 9sargramostim 6Temozolomide 6Dacarbazine 6montanide ISA 51 5MART-1 Antigen 5Blood Specimen Collection 5pembrolizumab 4Ranibizumab 4Melphalan 4Interleukin-2 4Carboplatin 4CTLA-4 Antigen 4Thalidomide 3Surveys and Questionnaires 3MAGEA3 protein, human 3Granulocyte-Macrophage Colony-Stimulating Factor 3AZD 6244 3sotrastaurin 2relatlimab 2gp100 Melanoma Antigen 2fludarabine phosphate 2fludarabine 2entinostat 2aflibercept 2Taxes 2Sunitinib 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Uveal Melanoma × Thalidomide × Clear all
NCT00005815 2013-06-19

Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
Dermatologic

Uveal Melanoma, Melanoma

NCT00238329 2013-04-08

PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
32 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT00072345 2013-01-18

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡